Semaglutide largely improved eating disorder symptoms in adults seeking obesity treatment, but a handful of cases still slipped into new or worsening pathology, according to data presented at Obesity Week 2026 and published November 15 in the International Journal of Eating Disorders.
The secondary analysis of 120 participants randomized to semaglutide 2.4 mg or placebo for 60 weeks found that binge eating and body image concerns generally improved more on the drug than on placebo, Medscape reported. Yet one person on semaglutide developed new vomiting episodes and two others reported excessive exercise — both had prior histories of those behaviors.
“Despite concerns that large, rapid weight losses could precipitate disordered eating and psychosocial complications, semaglutide, relative to placebo, showed larger improvements in several measures of disordered eating and body image concern,” said Kelly C. Allison, PhD, professor of psychiatry at the University of Pennsylvania’s Perelman School of Medicine and director of Penn’s Center for Weight and Eating Disorders.
“Onset of new eating disorder pathology was rare, as was worsening of existing pathology.”
The numbers behind the reassurance
At baseline, 6.9% of the semaglutide group and 12.5% of the placebo group met criteria for binge eating disorder (BED), with another 4.2% and 8.3% showing subthreshold BED. By week 60, none of the eight semaglutide participants with full or subthreshold BED at baseline still had the diagnosis at weeks 20 or 40, and 88% remained in remission at week 60 versus 75% in the placebo arm.
Among the 31 participants reporting any binge episodes before the trial, those on semaglutide were 45 to 51 percentage points more likely to be free of objective or subjective binges at weeks 40 and 60.

The semaglutide group also showed significantly greater reductions in the Eating Disorder Inventory Global Score, loss of control over eating, uncontrolled eating, emotional eating, and body image concerns including drive for thinness, body dissatisfaction, and weight concern (P < .05 at all three assessment points). No participant reported laxative or diuretic use at any visit.
Dropout complicated the picture: 84.7% of the semaglutide group completed the week 60 questionnaires versus 56.3% of the placebo group. “Unfortunately, there was higher dropout in the placebo group. These medications are quite effective with weight loss, and people suspect that they may be on placebo,” Allison told Medscape.
The imbalance and the 3:2 randomization ratio make the true incidence of new-onset binge eating uncertain, though rates appeared numerically higher with placebo — 18.5% versus 9.6% at week 60 among those with any baseline binge episodes.
Where the risk concentrates
The three semaglutide participants who developed concerning symptoms — one with four episodes of intentional vomiting and elevated drive for thinness and dietary restraint scores, two with excessive exercise — all had histories of those behaviors. Seven participants with past bulimia nervosa and 12 with past inappropriate compensatory behaviors reported no such episodes during the trial.
“We suggest eating disorder symptoms should be monitored in these at-risk individuals, whether treated by lifestyle modification alone or combined with incretin-based therapy, and they should be referred to an appropriate mental health professional if these complications arise.”
Kelly C. Allison, PhD, University of Pennsylvania
That recommendation mirrors the recently published consensus guidelines Allison co-authored, which advise screening all patients for current or past eating disorders before starting a GLP-1 agonist.
“Clinicians should feel comfortable asking people how their eating is going in a broad open way… people with restrictive eating disorders sometimes want to keep those behaviors to themselves but I think providers do need to be aware that this could be an issue,” she told Medscape.
The blind spot: restrictive eating
The session chair, Amin Sabet, MD, an endocrinologist and obesity medicine specialist who directs the Obesity Medicine Fellowship at the University of Massachusetts Chan Medical School, called the data “excellent and provide some reassurance that these drugs are low risk for causing disordered eating or worsening of disordered eating.”
But he flagged a critical gap: “We don’t know specifically how many people had a restrictive eating disorder at baseline or developed one during treatment… How do we identify people with existing or a history of restrictive eating disorders, which I think are not rare and more risky when we’re using these drugs?”
Allison pointed to a soon-to-be-published validated tool called Screening Kids’ and Teens’ Eating, designed to differentiate food restriction driven by GLP-1-related appetite suppression from restriction driven by an eating disorder. “So I would say be on the lookout for that,” she advised.
Real-world prescribing is already outpacing protocols
Separate survey data show why screening matters now. According to Bioengineer.org’s coverage of research published in The Lancet Regional Health – Western Pacific, a cross-sectional study found that roughly half of patients with binge eating disorder and approximately one third of individuals with atypical anorexia nervosa have already used a prescribed GLP-1 receptor agonist.
Those findings highlight “an emerging clinical reality in which prescribed metabolic agents intersect directly with disordered eating, despite the absence of an established clinical protocol for screening patients for an eating disorder history prior to prescribing,” the outlet noted.
Novo Nordisk supported the study, and Allison received investigator-sponsored research funding from the company on behalf of the University of Pennsylvania. Sabet reported equity holdings in Abbott Laboratories, AbbVie, Eli Lilly, Johnson & Johnson, Merck, and Novo Nordisk.
Allison earned her B.A. from the University of Notre Dame and her M.A. and Ph.D. from Miami University before joining the Perelman School of Medicine faculty. She directs the Center for Weight and Eating Disorders and has published more than 185 peer-reviewed papers and chapters along with two books.
Her research spans night eating syndrome, binge eating disorder, the timing of eating, and bariatric surgery outcomes, including a pilot randomized trial of liraglutide 3.0 mg for binge eating disorder. She is a Fellow of both the Academy for Eating Disorders and The Obesity Society.
Allison presents additional data from the trial at Obesity Week 2026 in Washington, D.C., this week.